10

15

CLAIMS

1.	A population of polynucleotides comprising at least one
polynucleotide	comprising a polynucleotide sequence selected from the group
-	EQ ID NOS. 1 through 40, or its respective complement.
,	
2.	The population of claim 1, wherein the one polynucleotide
comprises a nov	vel tag or its complement selected from the group consisting of
	to 26, 29, 32 to 35 or 38, or its respective complement.
_	
3.	An isolated polynucleotide comprising a polynucleotide sequence
selected from the	he group of sequences consisting of SEQ. ID. NOS:24 to 26, 29, 32
to 35 or 38, or	its respective complement.
4.	A gene delivery vehicle comprising an isolated polynucleotide of
any of claims 1	to 3.
5.	A host cell comprising an isolated polynucleotide of any of claims
1 to 3.	·
6.	An isolated polynucleotide comprising a polynucleotide sequence
	entification of larger fragment or full-length coding sequence of the
sequence depic	cted in SEQ ID NOS: 24 to 26, 29, 32 to 35 or 38, or its respective
complement.	
7.	An isolated second polynucleotide corresponding to the

25

20

- 7. An isolated second polynucleotide corresponding to the polynucleotide of claim 1.
 - 8. An isolated polynucleotide fragment of the polynucleotide of claim

30 7.

10

15

20

- 9. A polynucleotide according to claim 6 attached to a solid support.
- 10. A polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NOS: 24 to 26, 29, 32 to 35 or 38, or its respective complement attached to a solid support.
- 11. The polynucleotide of claim 10, wherein the solid support is a chip array.
- 12. An isolated polypeptide comprising a polypeptide encoded by the polynucleotide sequence of claim 6.
- 13. An antibody which recognizes an epitope on a polypeptide of claim
 12.
- polynucleotide isolated from a sample suspected of containing the lung cancer cell with a polynucleotide selected from the group consisting of SEQ ID NOS: 1 through 40, under conditions that favor hybridization of complementary polynucleotides and detecting a hybridized complement, wherein overexpression of the hybridized complement is indicative of the presence of a lung cancer cell.
- polynucleotide isolated from a sample suspected of containing the lung cancer cell with a polynucleotide obtained by identification of larger fragment or full-length coding sequences of the sequences selected from the group consisting of SEQ ID NOS: 1 through 40, under conditions that favor hybridization of complementary polynucleotides and detecting a hybridized complement, wherein overexpression of the hybridized complement is indicative of the presence of a lung cancer cell.

16. The method of claim 14 or 15, wherein the polynucleotide is immobilized on a solid support.

17. A method for detecting a lung cancer cell, comprising contacting a polynucleotide isolated from a sample suspected of containing the lung cancer cell with a polynucleotide selected from the group consisting of polynucleotides of SEQ ID NOS. 1 through 40, under conditions that favor hybridization; and amplifying complementary polynucleotides in the sample, wherein detection the amplified polynucleotides is indicative of a lung cancer cell.

10

15

5

polynucleotide isolated from a sample suspected of containing the lung cancer cell with a polynucleotide obtained by identification or larger fragment or full-length coding sequences of the polynucleotide sequences selected from the group consisting of polynucleotides of SEQ ID NOS. 1 through 40, under conditions that favor hybridization; and amplifying complementary polynucleotides in the sample, wherein detection the amplified polynucleotides is indicative of a lung cancer cell.

20

25

19. A method for detecting a lung cancer cell, comprising contacting a sample suspected of containing the lung cancer cell an agent that specifically binds to a gene product produced from a gene selected from the group consisting of carboxylesterase, NB1, 1GFbp5, HCG4, BST2, U2snrnp aux fac, 8-oxo-D-GTPase, GST sub 4 or GST 1 or GSTM 2, apolipe J or SP40 or trpm-2, or sulfated gp2, DSS1, thioredoxin reductase, B-myb, myeloblast mitochondrial outer memb protein, α-tubulin, p27, sox 2 or HMG box, epithelial memb proT 2/XMP, Na/K ATPase β subunit, glutathione perox-like protein, HSP90, and ODC-1, and detecting any agent:gene product complex so formed, thereby detecting a lung cancer cell.

10

15

20

25

- 20. The method of claim 18, wherein the agent is a monoclonal antibody.
- 21. A method for detecting a lung cancer cell, comprising contacting a sample suspected of containing the lung cancer cell with an agent that specifically binds to a gene product produced from a polynucleotide comprising a polynucleotide sequence obtained by identification of larger fragment or full-length coding sequence selected from the group consisting of SEQ ID NOS: 24 to 26, 29, 32 to 35 or 38, and detecting any agent:peptide complex so formed, thereby detecting a lung cancer cell.
- 22. The method for claim 21, wherein the agent is a monoclonal antibody.
- 23. A system for identifying selected polynucleotide records that identify a lung cancer cell, the system comprising:
 - a digital computer;
 - a database coupled to the computer;
- a database coupled to the database server having data stored therein, the data comprising records of data combined from polynucleotide obtained from the polynucleotide sequences comprising SEQ ID NOS: 1 to 40; and
- a code mechanism for applying queries based upon a desired selection criteria to the data file in the database to produce reports of polynucleotide records which match the desired selection criteria.
- 24. A method for detecting a lung cancer cell, using a computer having a processor, memory, display, and input/output devices, the method comprising the steps of:
- a) providing a sequence of a polynucleotide isolated from a sample suspected of containing a lung cancer cell;
 - b) providing the database of claim 23; and

10

15

20

25

- c) using a code mechanism for applying queries based upon a desired selection criteria to the data file in the database to produce reports of polynucleotide records of step a) which provide a match of the desired selection criteria of the sequences in the database of step b), the presence of a match being a positive indication that the polynucleotide of step a) has been isolated from a cell that is a lung cancer cell.
- 25. A screen for polynucleotides differentially expressed in lung cancer cells, comprising searching sequence databases for nucleotide sequences homologous to a polynucleotide selected from the group consisting of SEQ ID NOS: 1 through 40 and detecting sequences with homology thereby identifying polynucleotides differentially expressed in lung cancer cells.
- 26. A screen for a potential therapeutic agent for the reversal of the neoplastic condition of a lung cell wherein the cell is characterized by expression of a polynucleotide selected from the group consisting of the polynucleotides depicted in SEQ ID NOS. 1 through 40, comprising contacting a cell expressing the polynucleotide with an effective amount of a potential agent and assaying for reversal of the neoplastic condition.
- 27. A screen for a potential therapeutic agent for the reversal of the neoplastic condition of a lung cell wherein the cell is characterized by expression of a polynucleotide selected from the group consisting of the polynucleotides obtained by identification or larger fragment or full-length coding sequences of the sequences depicted in SEQ ID NOS: 1 to 40, comprising contacting a cell expressing the polynucleotide with an effective amount of a potential agent and assaying for reversal of the neoplastic condition.
- 28. A kit for use in a detection method according to any one of claims
 11 to 15 comprising in suitable packaging:

one or more polynucleotides selected from the group consisting of SEQ ID NOS: 1-40 immobilized on a solid support; and a reagent suitable for hybridizing a sample suspected of containing the lung cancer cell.

29. A non-human transgenic animal having a disruption in a polynucleotide corresponding to a polynucleotide having a sequence selected from the group consisting of SEQ ID NOS: 1-40.